Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis Eyes Expanded Menactra Indication Following Initial Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approves the meningococcal conjugate vaccine for patients 11-55 years old; Sanofi-Aventis will submit a sBLA for use in children ages 2-11 by February. The company is currently studying the vaccine in patients under age 2 and will initiate a study evaluating Menactra in subjects over age 55 years by January 2006.

You may also be interested in...



Sanofi Vaccine Sales Jump 50 Percent In Q3

Performance of vaccines business helps offset slight decline in pharmaceuticals revenues, hard hit by Ambien IR generics.

Sanofi Vaccine Sales Jump 50 Percent In Q3

Performance of vaccines business helps offset slight decline in pharmaceuticals revenues, hard hit by Ambien IR generics.

Sanofi’s Menactra Use Expanded To Children

Sanofi Pasteur’s meningococcal conjugate vaccine approved for use in children 2 years to 10 years old.

Related Content

Topics

UsernamePublicRestriction

Register

PS060888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel